{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:53:19Z","timestamp":1781650399322,"version":"3.54.5"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    <jats:bold>Abstract:<\/jats:bold>\n                    Ischemia-modified albumin (IMA) is a structurally altered form of human serum albumin produced within minutes of myocardial ischemia, well before the onset of irreversible cell injury detectable by cardiac troponin. Measured via the albumin cobalt-binding assay\u2014the first Food and Drug Administration-approved serum marker for cardiac ischemia\u2014IMA has been extensively investigated as an adjunct to electrocardiography and troponin for the early evaluation of acute chest pain in the emergency department. When used as part of a triple-test strategy combining IMA, troponin, and electrocardiogram, sensitivities exceeding 90\u201395% for acute coronary syndrome (ACS) exclusion have been reported, with 2 meta-analyses confirming significantly elevated IMA concentrations across ACS subtypes. Beyond diagnosis, IMA carries independent prognostic significance: elevated levels predict adverse outcomes at 1 year after acute myocardial infarction and correlate with the presence of critical coronary artery stenosis on angiography. IMA is not endorsed by current American College of Cardiology\/American Heart Association guidelines for ACS evaluation, largely because of its low specificity and marked elevation in noncardiac conditions including pulmonary embolism, stroke, and heart failure. This review examines clinical evidence for IMA in cardiovascular disease, critically appraises its diagnostic limitations, and discusses its potential role as a complementary biomarker of ischemia-without-necrosis in the era of high-sensitivity troponin.\n                  <\/jats:p>","DOI":"10.1097\/crd.0000000000001369","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:05:13Z","timestamp":1781647513000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Ischemia-Modified Albumin: Review of a Novel Cardiac Biomarker and Its Clinical Applications in Cardiovascular Disease"],"prefix":"10.1097","author":[{"given":"Muhammad Saad","family":"Furqan","sequence":"first","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY"},{"name":"Department of Medicine, Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY"},{"name":"Department of Medicine, Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"R1-20260616","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics\u20142017 update: a report from the American heart association.","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"R2-20260616","first-page":"1","article-title":"National Hospital ambulatory medical care survey: 2006 emergency department summary.","volume":"7","author":"Pitts","year":"2008","journal-title":"Natl Health Stat Rep"},{"key":"R3-20260616","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/jcp.2007.053363","article-title":"Ischaemia-modified albumin: clinical utility and pitfalls in measurement.","volume":"61","author":"Collinson","year":"2008","journal-title":"J Clin Pathol"},{"key":"R4-20260616","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0736-4679(00)00255-9","article-title":"A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia: a preliminary report.","volume":"19","author":"Bar-Or","year":"2000","journal-title":"J Emerg Med"},{"key":"R5-20260616","doi-asserted-by":"crossref","first-page":"9945424","DOI":"10.1155\/2021\/9945424","article-title":"Ischemia-modified albumin: origins and clinical implications.","volume":"2021","author":"Shevtsova","year":"2021","journal-title":"Dis Markers"},{"key":"R6-20260616","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/01.CIR.0000072764.18315.6B","article-title":"Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention.","volume":"107","author":"Sinha","year":"2003","journal-title":"Circulation"},{"key":"R7-20260616","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/clinchem\/47.3.464","article-title":"Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study.","volume":"47","author":"Christenson","year":"2001","journal-title":"Clin Chem"},{"key":"R8-20260616","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1179\/1351000213Y.0000000083","article-title":"Oxidative stress and ischemia-modified albumin in chronic ischemic heart failure.","volume":"19","author":"Ellidag","year":"2014","journal-title":"Redox Rep"},{"key":"R9-20260616","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/emj.2003.006007","article-title":"Role of \u201cischemia modified albumin,\u201d a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes.","volume":"21","author":"Sinha","year":"2004","journal-title":"Emerg Med J"},{"key":"R10-20260616","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ahj.2005.12.024","article-title":"Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department.","volume":"152","author":"Peacock","year":"2006","journal-title":"Am Heart J"},{"key":"R11-20260616","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.3390\/jcm11144205","article-title":"Serum concentrations of ischaemia-modified albumin in acute coronary syndrome: a systematic review and meta-analysis.","volume":"11","author":"Mangoni","year":"2022","journal-title":"J Clin Med"},{"key":"R12-20260616","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/medicina58050614","article-title":"Diagnostic accuracy of ischemia-modified albumin for acute coronary syndrome: a systematic review and meta-analysis.","volume":"58","author":"Shin","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"R13-20260616","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijcard.2004.05.042","article-title":"Ischemia modified albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T.","volume":"97","author":"Roy","year":"2004","journal-title":"Int J Cardiol"},{"key":"R14-20260616","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1503\/cmaj.045194","article-title":"Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome.","volume":"172","author":"Worster","year":"2005","journal-title":"CMAJ"},{"key":"R15-20260616","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s12291-013-0367-3","article-title":"Estimation of ischemia modified albumin (IMA) levels in patients with acute coronary syndrome.","volume":"29","author":"Gurumurthy","year":"2014","journal-title":"Indian J Clin Biochem"},{"key":"R16-20260616","doi-asserted-by":"crossref","first-page":"570","DOI":"10.14740\/jocmr3417w","article-title":"Ischemic modified albumin predicts critical coronary artery disease in unstable angina pectoris and non-ST-elevation myocardial infarction.","volume":"10","author":"Demirtas","year":"2018","journal-title":"J Clin Med Res"},{"key":"R17-20260616","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ahj.2009.12.026","article-title":"Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction: the French nationwide OPERA study.","volume":"159","author":"Van Belle","year":"2010","journal-title":"Am Heart J"},{"key":"R18-20260616","doi-asserted-by":"crossref","first-page":"611","DOI":"10.5152\/akd.2015.6156","article-title":"Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study.","volume":"15","author":"Cavusoglu","year":"2015","journal-title":"Anatol J Cardiol"},{"key":"R19-20260616","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.athoracsur.2016.10.051","article-title":"Heart-type fatty acid binding protein and ischemia-modified albumin for detection of myocardial infarction after coronary artery bypass graft surgery.","volume":"104","author":"Thielmann","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"R20-20260616","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes.","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R21-20260616","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2022.08.750","article-title":"2022 ACC expert consensus decision pathway on the evaluation and disposition of acute chest pain in the emergency department.","volume":"80","author":"Kontos","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R22-20260616","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1465-9921-9-49","article-title":"The value of ischemia-modified albumin compared with D-dimer in the diagnosis of pulmonary embolism.","volume":"9","author":"Turedi","year":"2008","journal-title":"Respir Res"},{"key":"R23-20260616","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/biom12050653","article-title":"A systematic review and meta-analysis of serum concentrations of ischaemia-modified albumin in acute ischaemic stroke, intracerebral haemorrhage, and subarachnoid haemorrhage.","volume":"12","author":"Mangoni","year":"2022","journal-title":"Biomolecules"},{"key":"R24-20260616","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3390\/medicina58050669","article-title":"Ischemia-modified albumin\u2014a potential new marker of oxidative stress in dermatological diseases.","volume":"58","author":"Tampa","year":"2022","journal-title":"Medicina (Kaunas, Lithuania)"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:05:16Z","timestamp":1781647516000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":24,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001369","relation":{},"ISSN":["1061-5377","1538-4683"],"issn-type":[{"value":"1061-5377","type":"print"},{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]}}}